

2019 Future of Dyskinesia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2FDEDF3B69DEN.html>

Date: February 2019

Pages: 130

Price: US\$ 2,199.00 (Single User License)

ID: 2FDEDF3B69DEN

Abstracts

The global demand for Dyskinesia treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Dyskinesia pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Dyskinesia pipeline companies from advancing their products into Phase 3 or Phase 4.

Dyskinesia Report Description-

The 2019 pipeline study on Dyskinesia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Dyskinesia pipeline compounds.

The Dyskinesia pipeline guide presents information on all active drugs currently being developed for Dyskinesia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Dyskinesia pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Dyskinesia drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Dyskinesia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Dyskinesia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Dyskinesia pipeline report includes-

An overview of Dyskinesia disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Dyskinesia pipeline

Company wise list of Dyskinesia pipeline

Mechanism of Action wise Dyskinesia pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Dyskinesia pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Dyskinesia pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Dyskinesia pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL DYSKINESIA PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Dyskinesia Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Dyskinesia pipeline, H1- 2019
- 3.5 Mechanism of Action wise Dyskinesia Pipeline Candidates

4 A2M PHARMA GMBH DYSKINESIA PIPELINE DETAILS

- 4.1 A2M Pharma GmbH Business Profile
- 4.2 A2M Pharma GmbH Dyskinesia Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ADDEX THERAPEUTICS LTD DYSKINESIA PIPELINE DETAILS

- 5.1 Addex Therapeutics Ltd Business Profile
- 5.2 Addex Therapeutics Ltd Dyskinesia Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 AMARANTUS BIOSCIENCE HOLDINGS INC DYSKINESIA PIPELINE DETAILS

- 6.1 Amaranthus Bioscience Holdings Inc Business Profile
- 6.2 Amaranthus Bioscience Holdings Inc Dyskinesia Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 ASTRAEA THERAPEUTICS LLC DYSKINESIA PIPELINE DETAILS

- 7.1 Astraea Therapeutics LLC Business Profile
- 7.2 Astraea Therapeutics LLC Dyskinesia Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 AVANIR PHARMACEUTICALS INC DYSKINESIA PIPELINE DETAILS

- 8.1 Avanir Pharmaceuticals Inc Business Profile
- 8.2 Avanir Pharmaceuticals Inc Dyskinesia Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 CADENT THERAPEUTICS DYSKINESIA PIPELINE DETAILS

- 9.1 Cadent Therapeutics Business Profile
- 9.2 Cadent Therapeutics Dyskinesia Drug Details
- 9.3 Drug Snapshot

- 9.3.1 Originator
- 9.3.2 Collaborator/Co-Developer
- 9.3.3 Route of Administration
- 9.3.4 Orphan Drug/Fast Track/Special Designation
- 9.3.5 Geography
- 9.3.6 Type of Molecular Entity
- 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 CAVION LLC DYSKINESIA PIPELINE DETAILS

- 10.1 Cavion LLC Business Profile
- 10.2 Cavion LLC Dyskinesia Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 CEREVANCE INC DYSKINESIA PIPELINE DETAILS

- 11.1 Cerevance Inc Business Profile
- 11.2 Cerevance Inc Dyskinesia Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography

- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 CLEVEXEL PHARMA SAS DYSKINESIA PIPELINE DETAILS

- 12.1 Clevexel Pharma SAS Business Profile
- 12.2 Clevexel Pharma SAS Dyskinesia Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 CONTERA PHARMA APS DYSKINESIA PIPELINE DETAILS

- 13.1 Contera Pharma ApS Business Profile
- 13.2 Contera Pharma ApS Dyskinesia Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14 EPIVAX INC DYSKINESIA PIPELINE DETAILS

14.1 EpiVax Inc Business Profile

14.2 EpiVax Inc Dyskinesia Drug Details

14.3 Drug Snapshot

14.3.1 Originator

14.3.2 Collaborator/Co-Developer

14.3.3 Route of Administration

14.3.4 Orphan Drug/Fast Track/Special Designation

14.3.5 Geography

14.3.6 Type of Molecular Entity

14.3.7 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15 H. LUNDBECK AS DYSKINESIA PIPELINE DETAILS

15.1 H. Lundbeck AS Business Profile

15.2 H. Lundbeck AS Dyskinesia Drug Details

15.3 Drug Snapshot

15.3.1 Originator

15.3.2 Collaborator/Co-Developer

15.3.3 Route of Administration

15.3.4 Orphan Drug/Fast Track/Special Designation

15.3.5 Geography

15.3.6 Type of Molecular Entity

15.3.7 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16 HUA MEDICINE (SHANGHAI) LTD DYSKINESIA PIPELINE DETAILS

16.1 Hua Medicine (Shanghai) Ltd Business Profile

16.2 Hua Medicine (Shanghai) Ltd Dyskinesia Drug Details

16.3 Drug Snapshot

16.3.1 Originator

16.3.2 Collaborator/Co-Developer

16.3.3 Route of Administration

16.3.4 Orphan Drug/Fast Track/Special Designation

16.3.5 Geography

16.3.6 Type of Molecular Entity

16.3.7 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

17 INDIA GLOBALIZATION CAPITAL INC DYSKINESIA PIPELINE DETAILS

17.1 India Globalization Capital Inc Business Profile

17.2 India Globalization Capital Inc Dyskinesia Drug Details

17.3 Drug Snapshot

17.3.1 Originator

17.3.2 Collaborator/Co-Developer

17.3.3 Route of Administration

17.3.4 Orphan Drug/Fast Track/Special Designation

17.3.5 Geography

17.3.6 Type of Molecular Entity

17.3.7 Current Status

17.4 Drug Overview

17.5 Drug Mechanism of Action

17.6 Clinical/Pre-clinical Trial Details

17.7 Latest Drug Developments

18 IRLAB THERAPEUTICS AB DYSKINESIA PIPELINE DETAILS

18.1 IRLAB Therapeutics AB Business Profile

18.2 IRLAB Therapeutics AB Dyskinesia Drug Details

18.3 Drug Snapshot

18.3.1 Originator

18.3.2 Collaborator/Co-Developer

18.3.3 Route of Administration

- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 JUNAXO INC DYSKINESIA PIPELINE DETAILS

- 19.1 Junaxo Inc Business Profile
- 19.2 Junaxo Inc Dyskinesia Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 MELIOR PHARMACEUTICALS II LLC DYSKINESIA PIPELINE DETAILS

- 20.1 Melior Pharmaceuticals II LLC Business Profile
- 20.2 Melior Pharmaceuticals II LLC Dyskinesia Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status
- 20.4 Drug Overview

- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 MENTINOVA INC DYSKINESIA PIPELINE DETAILS

- 21.1 MentiNova Inc Business Profile
- 21.2 MentiNova Inc Dyskinesia Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 MERZ PHARMA GMBH & CO. KGAA DYSKINESIA PIPELINE DETAILS

- 22.1 Merz Pharma GmbH & Co. KgaA Business Profile
- 22.2 Merz Pharma GmbH & Co. KgaA Dyskinesia Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity
 - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 MITODYS THERAPEUTICS LTD DYSKINESIA PIPELINE DETAILS

- 23.1 MitoDys Therapeutics Ltd Business Profile
- 23.2 MitoDys Therapeutics Ltd Dyskinesia Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 MYLAN NV DYSKINESIA PIPELINE DETAILS

- 24.1 Mylan NV Business Profile
- 24.2 Mylan NV Dyskinesia Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25 NEURIM PHARMACEUTICALS LTD DYSKINESIA PIPELINE DETAILS

- 25.1 Neurim Pharmaceuticals Ltd Business Profile
- 25.2 Neurim Pharmaceuticals Ltd Dyskinesia Drug Details
- 25.3 Drug Snapshot
 - 25.3.1 Originator

- 25.3.2 Collaborator/Co-Developer
- 25.3.3 Route of Administration
- 25.3.4 Orphan Drug/Fast Track/Special Designation
- 25.3.5 Geography
- 25.3.6 Type of Molecular Entity
- 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26 NEUROCRINE BIOSCIENCES INC DYSKINESIA PIPELINE DETAILS

- 26.1 Neurocrine Biosciences Inc Business Profile
- 26.2 Neurocrine Biosciences Inc Dyskinesia Drug Details
- 26.3 Drug Snapshot
 - 26.3.1 Originator
 - 26.3.2 Collaborator/Co-Developer
 - 26.3.3 Route of Administration
 - 26.3.4 Orphan Drug/Fast Track/Special Designation
 - 26.3.5 Geography
 - 26.3.6 Type of Molecular Entity
 - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27 NEUROLIXIS INC DYSKINESIA PIPELINE DETAILS

- 27.1 Neurolix Inc Business Profile
- 27.2 Neurolix Inc Dyskinesia Drug Details
- 27.3 Drug Snapshot
 - 27.3.1 Originator
 - 27.3.2 Collaborator/Co-Developer
 - 27.3.3 Route of Administration
 - 27.3.4 Orphan Drug/Fast Track/Special Designation
 - 27.3.5 Geography
 - 27.3.6 Type of Molecular Entity

- 27.3.7 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28 NEWRON PHARMACEUTICALS SPA DYSKINESIA PIPELINE DETAILS

- 28.1 Newron Pharmaceuticals SpA Business Profile
- 28.2 Newron Pharmaceuticals SpA Dyskinesia Drug Details
- 28.3 Drug Snapshot
 - 28.3.1 Originator
 - 28.3.2 Collaborator/Co-Developer
 - 28.3.3 Route of Administration
 - 28.3.4 Orphan Drug/Fast Track/Special Designation
 - 28.3.5 Geography
 - 28.3.6 Type of Molecular Entity
 - 28.3.7 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

29 PHENOMENOME DISCOVERIES INC DYSKINESIA PIPELINE DETAILS

- 29.1 Phenomenome Discoveries Inc Business Profile
- 29.2 Phenomenome Discoveries Inc Dyskinesia Drug Details
- 29.3 Drug Snapshot
 - 29.3.1 Originator
 - 29.3.2 Collaborator/Co-Developer
 - 29.3.3 Route of Administration
 - 29.3.4 Orphan Drug/Fast Track/Special Designation
 - 29.3.5 Geography
 - 29.3.6 Type of Molecular Entity
 - 29.3.7 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action
- 29.6 Clinical/Pre-clinical Trial Details
- 29.7 Latest Drug Developments

30 POLYCORE THERAPEUTICS LLC DYSKINESIA PIPELINE DETAILS

- 30.1 PolyCore Therapeutics LLC Business Profile
- 30.2 PolyCore Therapeutics LLC Dyskinesia Drug Details
- 30.3 Drug Snapshot
 - 30.3.1 Originator
 - 30.3.2 Collaborator/Co-Developer
 - 30.3.3 Route of Administration
 - 30.3.4 Orphan Drug/Fast Track/Special Designation
 - 30.3.5 Geography
 - 30.3.6 Type of Molecular Entity
 - 30.3.7 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31 REVANCE THERAPEUTICS INC DYSKINESIA PIPELINE DETAILS

- 31.1 Revance Therapeutics Inc Business Profile
- 31.2 Revance Therapeutics Inc Dyskinesia Drug Details
- 31.3 Drug Snapshot
 - 31.3.1 Originator
 - 31.3.2 Collaborator/Co-Developer
 - 31.3.3 Route of Administration
 - 31.3.4 Orphan Drug/Fast Track/Special Designation
 - 31.3.5 Geography
 - 31.3.6 Type of Molecular Entity
 - 31.3.7 Current Status
- 31.4 Drug Overview
- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

32 SAGE THERAPEUTICS INC DYSKINESIA PIPELINE DETAILS

- 32.1 Sage Therapeutics Inc Business Profile
- 32.2 Sage Therapeutics Inc Dyskinesia Drug Details

- 32.3 Drug Snapshot
 - 32.3.1 Originator
 - 32.3.2 Collaborator/Co-Developer
 - 32.3.3 Route of Administration
 - 32.3.4 Orphan Drug/Fast Track/Special Designation
 - 32.3.5 Geography
 - 32.3.6 Type of Molecular Entity
 - 32.3.7 Current Status
- 32.4 Drug Overview
- 32.5 Drug Mechanism of Action
- 32.6 Clinical/Pre-clinical Trial Details
- 32.7 Latest Drug Developments

33 SALUBRX THERAPEUTICS INC DYSKINESIA PIPELINE DETAILS

- 33.1 SalubRx Therapeutics Inc Business Profile
- 33.2 SalubRx Therapeutics Inc Dyskinesia Drug Details
- 33.3 Drug Snapshot
 - 33.3.1 Originator
 - 33.3.2 Collaborator/Co-Developer
 - 33.3.3 Route of Administration
 - 33.3.4 Orphan Drug/Fast Track/Special Designation
 - 33.3.5 Geography
 - 33.3.6 Type of Molecular Entity
 - 33.3.7 Current Status
- 33.4 Drug Overview
- 33.5 Drug Mechanism of Action
- 33.6 Clinical/Pre-clinical Trial Details
- 33.7 Latest Drug Developments

34 SOM BIOTECH SL DYSKINESIA PIPELINE DETAILS

- 34.1 SOM Biotech SL Business Profile
- 34.2 SOM Biotech SL Dyskinesia Drug Details
- 34.3 Drug Snapshot
 - 34.3.1 Originator
 - 34.3.2 Collaborator/Co-Developer
 - 34.3.3 Route of Administration
 - 34.3.4 Orphan Drug/Fast Track/Special Designation

- 34.3.5 Geography
- 34.3.6 Type of Molecular Entity
- 34.3.7 Current Status
- 34.4 Drug Overview
- 34.5 Drug Mechanism of Action
- 34.6 Clinical/Pre-clinical Trial Details
- 34.7 Latest Drug Developments

35 ULTRAGENYX PHARMACEUTICAL INC DYSKINESIA PIPELINE DETAILS

- 35.1 Ultragenyx Pharmaceutical Inc Business Profile
- 35.2 Ultragenyx Pharmaceutical Inc Dyskinesia Drug Details
- 35.3 Drug Snapshot
 - 35.3.1 Originator
 - 35.3.2 Collaborator/Co-Developer
 - 35.3.3 Route of Administration
 - 35.3.4 Orphan Drug/Fast Track/Special Designation
 - 35.3.5 Geography
 - 35.3.6 Type of Molecular Entity
 - 35.3.7 Current Status
- 35.4 Drug Overview
- 35.5 Drug Mechanism of Action
- 35.6 Clinical/Pre-clinical Trial Details
- 35.7 Latest Drug Developments

36. LATEST DYSKINESIA DRUG PIPELINE DEVELOPMENTS, 2019

37. APPENDIX

- 37.1 About Us
- 37.2 Sources and Methodology
- 37.3 Contact Information

I would like to order

Product name: 2019 Future of Dyskinesia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2FDEDF3B69DEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2FDEDF3B69DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

